Explore

Rapid Read Rapid Read
Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Women

Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Women

A recent study published in the JCO Oncology Practice journal indicates that GLP-1 medications, commonly used for weight loss, may be associated with a reduced risk of developing breast cancer. The study analyzed health records from over 111,000 women aged 45 to 80 who were overweight or obese. Findings suggest that women using GLP-1 drugs had a 30% lower risk of developing breast cancer. Dr. Tara Narula, ABC News chief medical correspondent, explained that GLP-1 medications help reduce weight, inflammation, and improve insulin sensitivity, which could potentially lower breast cancer risk. However, the study's lead author, Dr. Elizabeth McDonald, emphasized that the findings are observational and do not definitively confirm a causal relationship.
Rapid Read Rapid Read
Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Overweight Women

Study Suggests GLP-1 Medications May Lower Breast Cancer Risk in Overweight Women

A recent study published in the JCO Oncology Practice journal indicates that GLP-1 medications, commonly used for weight loss, may be linked to a reduced risk of developing breast cancer. The study analyzed health records from over 111,000 women aged 45 to 80 within the University of Pennsylvania Health System. These women were either overweight or obese, and the study aimed to observe who developed breast cancer over several years. The findings suggest that women using GLP-1 medications had a 30% lower risk of developing breast cancer. Dr. Tara Narula, ABC News chief medical correspondent, explained that GLP-1s might reduce breast cancer risk by decreasing weight, inflammation, and improving insulin sensitivity. However, the study's lead author, Dr. Elizabeth McDonald, emphasized that the findings are observational and do not definitively confirm a causal relationship. The study adds to existing research suggesting the potential of GLP-1s as cancer prevention tools.
Vox Vox
How Americans got hooked on “drive-thru” healthcare

How Americans got hooked on “drive-thru” healthcare

When did getting a prescription start to feel like ordering at McDonald’s?
Discover daily Discover daily
From No. 1 Hit to Timeless Favorite: Ray Charles' Classic Track

From No. 1 Hit to Timeless Favorite: Ray Charles' Classic Track

The song "I Can't Stop Loving You" has a rich history that spans decades, beginning with its creation by country musician Don Gibson in 1957. This ...
AP News AP News
Some Republican governors are rebranding June with conservative alternatives to Pride

Some Republican governors are rebranding June with conservative alternatives to Pride

June is Pride Month across the U.S. But in some Republican-controlled states it's now officially Fidelity, Nuclear Family or Strong Families Month
Rapid Read Rapid Read
Workit Health's Home Delivery Program Enhances Treatment Retention for Opioid Use Disorder

Workit Health's Home Delivery Program Enhances Treatment Retention for Opioid Use Disorder

Workit Health, a telehealth provider specializing in opioid and alcohol use disorder treatment, has implemented a home delivery program for buprenorphine, a medication used in opioid addiction treatment. A study published in February 2025 in Addiction Science & Clinical Practice found that patients receiving buprenorphine through home delivery had significantly higher retention rates compared to those picking up prescriptions at retail pharmacies. The study reported a three-month retention rate of 82.6% for home delivery patients versus 58.9% for pharmacy pickup patients. This initiative addresses the issue of many U.S. pharmacies not stocking buprenorphine, which can lead to delays in treatment for patients relying on telehealth prescriptions.
Reuters Reuters
Exclusive-Cigna drops coverage of GLP-1 obesity drugs for its own employees

Exclusive-Cigna drops coverage of GLP-1 obesity drugs for its own employees

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan effective July 1, according to materials viewed by Reuters on Tuesday.
Rapid Read Rapid Read
Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

Study Finds GLP-1 Drugs May Reduce Breast Cancer Risk by 30%

A study from the University of Pennsylvania's Perelman School of Medicine has found that women taking GLP-1 medications, commonly used for weight loss, are 30% less likely to develop breast cancer. The analysis involved over 110,000 women aged 45 to 80, revealing that these drugs, while not originally designed for cancer therapy, affect pathways associated with cancer development. The findings suggest potential for GLP-1 drugs as preventive treatments for high-risk women, although further clinical trials are needed to confirm their efficacy in cancer prevention.
Trendline Trendline
Noom Introduces At-Home Biomarker Test Kit for Metabolic Health Monitoring

Noom Introduces At-Home Biomarker Test Kit for Metabolic Health Monitoring

Noom Introduces At-Home Biomarker Test Kit for Metabolic Health Monitoring
AP News AP News
Attitudes toward same-sex marriage and transgender issues are shifting, Gallup poll shows

Attitudes toward same-sex marriage and transgender issues are shifting, Gallup poll shows

A new Gallup poll finds support for same-sex marriage and relationships in the U.S. has stopped rising after two decades
AP News AP News
After decades of rising support, same-sex marriage acceptance may be stalling, Gallup poll shows

After decades of rising support, same-sex marriage acceptance may be stalling, Gallup poll shows

A new Gallup poll finds support for same-sex marriage and relationships in the U.S. has stopped rising after two decades
Trendline Trendline
Costco Sees Surge in Protein Sales Amid Looming Whey Shortages

Costco Sees Surge in Protein Sales Amid Looming Whey Shortages

Costco Sees Surge in Protein Sales Amid Looming Whey Shortages